Orbax® — veterinary medication

Overview

Source: Animal Drugs @ FDA

Proprietary name

Orbax®

Active ingredient

Orbifloxacin

Application type

NADA

Sponsor

Intervet, Inc.

Applications on record

1

First published

June 1, 2016

Adverse event reports

Source: openFDA VeDDRA

804

Reports mentioning this ingredient

July 10, 1997 – March 23, 2026

118

Classified serious

per reporter assessment

70

Lack of expected efficacy

resistance signal

17

Human operator exposure

needle-stick or splash

Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “ORBIFLOXACIN”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term)	Reports	Relative frequency
Vomiting	77
Anorexia	65
Blindness	65
Depression	64
Death	57
Death by euthanasia	55
Convulsion	54
Mydriasis	45
Ataxia	40
Lack of efficacy (bacteria) - NOS	36
Vials, Damaged	35
Retinal disorder NOS	25
Hypersalivation	23
Vials, Leaking	21
Diarrhoea	20
Temporary blindness	19
Confusion	17
Pruritus	16
Trembling	16
Accidental exposure	16

Species affected

Source: openFDA VeDDRA

Cat 423 Dog 265 Human 6 Other 5 Rabbit 2 Guinea Pig 2 Bobcat 1

Regulatory context

New Animal Drug Application (NADA). A pioneer approval evaluated for target animal safety, therapeutic effectiveness, manufacturing controls and — for food-producing species — human food safety including residue depletion.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA	FDA CVM	Applications, sponsor, status, withdrawal
Animal & Veterinary Events	FDA CVM	VeDDRA adverse event aggregates by active ingredient